AtCor wins $1.1m deal for SphygmoCor XCEL
Wednesday, 15 August, 2012
AtCor Medical (ASX:ACG) has secured a $1.1 million contract to provide its SphygmoCor XCEL cardiac monitoring system to an international pharmaceutical company.
The deal covers the supply of SphygmoCor XCEL systems as well as clinical trial support services. The pharmaceutical company in question has not been named.
SphyhmoCor XCEL is the improved version of AtCor's SphygmoCor central aortic blood pressure and arterial stiffness monitoring system.
The upgraded system automates and improves the process of data capturing, and can allow simultaneous brachial and central aortic blood pressure measurement. SphygmoCor XCEL was launched in May, in Australia, Europe and some Asian markets, and AtCor filed for FDA approval for the system late last month.
SphygmoCor is used by clinicians as a cardiac disease risk assessment tool, as well as in medical research and clinical trials. Around 2,700 systems are in use worldwide.
AtCor was founded in Sydney in 1994, and went public via a $15 million IPO in 2005. The company also has operations in the US and Europe.
AtCor Medical (ASX:ACG) shares were trading unchanged at $0.060 as of around 3pm on Tuesday.
High folic acid in pregnancy could cause early bleeding
Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...
Genetics shape our personality and life outcomes more than we thought
Scientists have identified >1200 genetic variants associated with personality traits,...
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
